Is Stereotaxis, Inc. overvalued or undervalued?

As of 9 May 2019, the valuation grade for Stereotaxis, Inc. moved from very expensive to risky, indicating a significant change in its financial outlook. The company is currently considered overvalued. Key ratios highlight this concern, with a price-to-book value of 23.67, an EV to EBITDA of -7.42, and a staggering ROE of -310.19%.
When compared to peers, Stereotaxis, Inc. has a less favorable position, with Jin Medical International Ltd. showing a more reasonable EV to EBITDA of -14.24, while Butterfly Network, Inc. also reflects a risky valuation with an EV to EBITDA of -6.90. The company's recent stock performance has been underwhelming, with a year-to-date return of -7.46% compared to the S&P 500's 2.44%, further reinforcing the notion that it is overvalued in the current market context.